Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

bulevirtide

Details

Generic Name:
bulevirtide
Project Status:
Pending
Therapeutic Area:
chronic hepatitis delta virus (HDV) infection
Manufacturer:
Gilead Sciences Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Hepcludex
Project Line:
Reimbursement Review
Project Number:
SR0881-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Bulevirtide is anticipated to be indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Bulevirtide is anticipated to be indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 22, 2025